Navigation Links
Malaria against malaria: A pre-existing malaria infection can prevent a second infection
Date:5/15/2011

rasites causing the parasites in the liver to be starved of iron, so that they cannot grow. In that respect, the results challenge the biological concept that infection of distinct host cells (liver hepatocytes or red blood cells) occur independently from each other, which may also have impact in the research area of infection (beyond malaria).

Dr Silvia Portugal, first author of the study says: "I am very happy that we were able to find such an interesting interaction occurring between different malaria parasite stages in a single host, and that this might contribute for future control of malaria."

Dr Maria Mota, who led the study at Instituto de Medicina Molecular in Lisbon says: "Our findings help explaining the differences in infection risk and complexity of infections in young individuals observed in endemic-malaria regions that have hitherto required speculative explanations. Also, they challenge the idea that infection in distinct cell types is independent, which may have an impact in future research in the field of infectious diseases as a whole. "

Dr Hal Drakesmith who co-led the study at the Weatherall Institute of Molecular Medicine adds: "'Now that we understand how malaria parasites protect their territory in the body from competitor parasites, we may be able to enhance this natural defence mechanism to combat the risk of malaria infections. At the same time we may need to look again at the advisability of iron supplementation programmes in malaria-endemic regions, as possible increased risk of infection may need to be weighed against benefits - more data is needed on this issue."

Malaria is a devastating disease that affects extensive areas of Africa, Asia, South and Central America, causing several thousands of deaths per year in children under the age of five. Malaria is caused by the infection of the protozoan parasite Plasmodium, which belongs to the phylum Apicomplexa. Attempts to eradicate malaria have so far b
'/>"/>

Contact: Marta Agostinho
marta-elisa@fm.ul.pt
351-918-486-058
Instituto de Medicina Molecular
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. €12 million ($16.9 million) project to develop new tools for malaria control
2. Insight into parasite family planning could help target malaria
3. Antifungal compound found on tropical seaweed has promising antimalarial properties
4. Floating spores kill malaria mosquito larvae
5. University of South Florida and Draper team to create advanced devices for testing malaria drugs
6. Malaria medication may help against 1 type of frontotemporal dementia
7. Malaria modeling and control focus of workshop
8. Malaria-infected cells stiffen, block blood flow
9. New study examines immunity in emerging species of a major mosquito carrer of malaria
10. Researchers link cerebral malaria to epilepsy, behavior disorders
11. UC Riverside cell biologist to investigate how malaria parasite multiplies in red blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Researchers from the University of Illinois at Chicago have ... role in breaking down and inhibiting the formation of ... was published online this week in Nature Cell ... specialized cells are "recruited" to the wound site that ...
... and watched electrons flow through them, proving that single-molecule ... nanoscale science experiments. The finding, reported in the ... probes the effects of strong electron interactions that can ... size limit--single-molecule devices. The work resulted in the first ...
... National Eye Institute (NEI), part of the National Institutes ... translate molecular and genetic approaches from the laboratory to ... director Francis S. Collins, M.D., Ph.D., will deliver a ... feature discussions about cutting-edge treatment strategies as well as ...
Cached Biology News:Researchers discover mechanism that limits scar formation 2Stretching molecules yields new understanding of electricity 2National Eye Institute hosts Translational Research and Vision Symposium 2
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... WASHINGTON, June 15 Congressional Quarterly presents a 360-degree ... of follow-on versions of biotech drugs. This CQ Forum ... interest groups, and leading researchers regarding the complex structures ... possible? Will the availability of these products save money ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... of shares of convertible preferred stock pursuant to a registered ... of approximately $2 million. The preferred stock is convertible into ... investor at a price of $0.1105 per share. , ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), ... oncology, today reported that patient follow-up in the open-label ... in benign prostatic hyperplasia (BPH) with its lead endocrinology ... the end of this week. Therefore, data analysis and ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Request Info...
... is a fast and efficient ... Its high capacity and reliable design ... walk away time than typical stackers. ... set-up make for a seamless and ...
... MLF1 Interacting Protein/PBIP1 (phospho T78) ( ... Antigen: Synthetic ... 73-83 of Human MLF1 Interacting Protein ... 359815 Swiss ...
Biology Products: